FP-025:Asthma; COPD/ILD

FP-025 is a highly selective (non-hydroxamate), oral non-competitive small molecule inhibitor of Matrix Metalloproteinase-12/Macrophage elastase (MMP-12). This enzyme is a crucial mediator of matrix degradation and remodeling in both normal development and maintenance.

For detailed Phase 1 studies design, please visit:

Single ascending dose (SAD):
https://clinicaltrials.gov/ct2/show/NCT02238834?term=FP-025&rank=1
(Identifier:NCT02238834)

Multiple ascending dose (MAD):
https://clinicaltrials.gov/ct2/show/NCT03304964?term=FP-025&rank=2
(Identifier:NCT03304964)

For detailed Phase 2 study design, please visit:

https://clinicaltrials.gov/ct2/show/NCT03858686?term=FP-025&rank=1
(Identifier: NCT03858686)


Asthma and acute exacerbation of COPD

Asthma and chronic obstructive pulmonary disease (COPD) are two of the most common lung diseases in the world. Asthma, a chronic inflammatory disease of the trachea, is characterized by varying and recurrent symptoms, reversible airflow obstruction, and bronchospasm; COPD, a multifocal and multicentric chronic respiratory disease, can result in high disability and mortality rates. In recent years, countries worldwide have eyed the great importance of chronic obstructive pulmonary disease (COPD) because of its high and increasing prevalence.

In asthma and COPD patients, the expression of MMP-12 in their lungs is significantly higher than in normal controls, accompanied by the activation of eosinophils and airway inflammation. Eosinophils can cause respiratory muscle tension in asthma patients and can also cause neutrophilic inflammatory response in COPD patients. Highly selective MMP-12 inhibitors can suppress eosinophilic inflammation, which has the potential to treat asthma and COPD. 

So far in the market, there is yet to have any treatment that can modify the progression of asthma and COPD. Most available therapies involve bronchodilators and inhaled steroids, which are only symptom-relief medications. There remains a significant unmet medical need for both asthma and COPD. The highly selective MMP-12 inhibitor developed by Foresee will be a new type of drug with the potential to revolutionize the treatment method for patients with asthma and COPD. 

Acute exacerbation of COPD is "an acute event” characterized by worsening the patient's respiratory symptoms beyond normal day-to-day variations. This generally includes an acute change in one or more of the following cardinal symptoms: cough increases in frequency and severity, sputum production increases in volume and/or changes character, and dyspnea increases. This condition leads to a change in medication. Additional use of FP-025 may alleviate or reduce COPD exacerbation symptoms and frequency.